This content has been funded and created by AstraZeneca. Intended for US healthcare professionals only. Based on US clinical practice guidelines and reflects the management of patients in the United States. For educational purposes only; not a substitute for independent clinical judgment.
Three patients. One decision at a time. In LungPath, you’ll work up three complex lung cancer cases from first presentation through imaging, biopsy, staging, and biomarker testing, choosing between two paths at every turn. See how your calls stack up against your peers at each step, then put your clinical knowledge to the test across the evolving landscape of lung cancer.
US-114752 Last Updated 8/26
